Abstract 685: GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-685
Abstract: Background: GD2-directed immunotherapeutic strategies have improved outcomes in neuroblastoma; however, the majority of patients treated suffer relapse and GD2 expression on pain fibers causes dose-limiting toxicities. Methods: To identify alternative cell surface immunotherapeutic targets, we… read more here.
Keywords: immunotherapeutic target; oncogene immunotherapeutic; high risk; gpc2 oncogene ... See more keywords
TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15102735
Abstract: Simple Summary T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) acts as an immune checkpoint on exhausted T cells and has been associated with dismal outcomes in various solid tumors. TIM3 is currently being… read more here.
Keywords: immunotherapeutic target; cell; sts tim; expression ... See more keywords